Bavarian Nordic (OTCMKTS:BVNRY) Shares Gap Down – Time to Sell?

Bavarian Nordic (OTCMKTS:BVNRY) gapped down prior to trading on Wednesday . The stock had previously closed at $9.86, but opened at $9.57. Bavarian Nordic shares last traded at $9.7650, with a volume of 650 shares trading hands.

Bavarian Nordic Trading Down 1.0%

The company has a market capitalization of $2.32 billion, a P/E ratio of 6.30 and a beta of 1.37. The firm’s 50 day moving average price is $10.41 and its two-hundred day moving average price is $10.87.

Bavarian Nordic (OTCMKTS:BVNRY) last announced its quarterly earnings data on Friday, November 14th. The company reported $0.72 EPS for the quarter. Bavarian Nordic had a net margin of 35.96% and a return on equity of 20.47%. The business had revenue of $281.11 million for the quarter. Analysts anticipate that Bavarian Nordic will post 0.67 earnings per share for the current fiscal year.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.